Bernard serves as the chief technology officer at Curie Therapeutics. Prior to joining Curie, Bernard was president and chief operating officer of Telix Pharmaceuticals’ U.S. business. In this role he led regulatory and commercial operations for its clinical stage and marketed products in renal, prostate, and brain cancer and led the US team to the FDA approval of the prostate imaging radiopharmaceutical Illuccix®. Prior to this, he was vice president, CMC and Radiopharmaceutical Development at Zevacor Pharma, Zevacor Molecular and IBA Molecular. Bernard brings over 20 years of experience in all phases of both small molecule and antibody based-radiopharmaceutical drug development, from the earliest stages of discovery through to New Drug Application (NDA) and commercial launches. Bernard received his Ph.D. in chemistry from the University of Liège.